Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications

US 20040234587A1
Filed: 07/15/2004
Published: 11/25/2004
Est. Priority Date: 07/27/2001
Status: Active Grant

First Claim

Patent Images

1. A composition, comprising:

(a) a phospholipid of the general formula (I), wherein X is —

CH₂CH₂NH₃, —

CH₂CH₂N(CH₃)₃or (b) a flavonoid of the general formula (II),

View all claims

4 Assignments

Timeline View

Assignment View

0 Petitions

Accused Products

Abstract

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

79 Citations

View as Search Results

128 Claims

1. A composition, comprising:
- (a) a phospholipid of the general formula (I), wherein X is —
  
  CH₂CH₂NH₃, —
  
  CH₂CH₂N(CH₃)₃or (b) a flavonoid of the general formula (II),
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 115, 116, 117, 118, 119, 121, 122, 123, 124, 125, 126, 127, 128)
- - 2. The composition according to claim 1, wherein the composition is derived from a marine or aquatic biomass.
  - 3. The composition according to claim 2, wherein the biomass is crustaceans.
  - 4. The composition as according to claim 2, wherein the biomass is zooplankton.
  - 5. The composition according to claim 4, wherein the zooplankton is krill.
  - 6. The composition according to claim 2, wherein the composition is derived from initial processing of the biomass.
  - 7. The composition according to claim 6, wherein the processing is conducted at a temperature of about 5°
    - C. or less.
  - 8. The composition according to claim 6, wherein the composition is derived from the biomass grease.
  - 9. The composition according to claim 1, comprising at least about 40% w/w phospholipid.
  - 10. The composition according to claim 9, comprising at least about 45% w/w phospholipid.
  - 11. The composition according to claim 10, comprising from about 45 to 60% w/w phospholipid.
  - 12. The composition according to claim 1, wherein the phospholipid comprises phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, sphingomyelin or a mixture thereof.
  - 13. The composition according to claim 1, wherein the phospholipid comprises saturated, monounsaturated or polyunsaturated fatty acids.
  - 14. The composition according to claim 13, wherein the polyunsaturated fatty acids are selected from the group consisting of omega-3 and omega-6 fatty acids.
  - 15. The composition according to claim 13, wherein the polyunsaturated fatty acids are selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), myristic acid, myristoleic acid, lignoceric acid, linolenic acid, alpha linolenic acid, nervonic acid, linoleic acid, oleic acid, stearic acid, palmitic acid and palmitoleic acid.
  - 16. The composition according to claim 1, wherein the phospholipid further comprises an additional lipid component.
  - 17. The composition according to claim 16, wherein the additional lipid component is a monoglyceride, triglyceride, cholesterol or a mixture thereof.
  - 18. The composition according to claim 1, further comprising at least about 4% w/w of free fatty acids.
  - 19. The composition according to claim 18, comprising at least about 5% w/w of free fatty acids.
  - 20. The composition according to claim 1, wherein polyunsaturated fatty acids comprise at least about 15% w/w of the total lipids in the composition.
  - 21. The composition according to claim 20, wherein polyunsaturated fatty acids comprise at least about 40% w/w of the total lipids in the composition.
  - 22. The composition according to claim 21, wherein polyunsaturated fatty acids comprise at least about 45% w/w of the total lipids in the composition.
  - 23. The composition according to claim 20, wherein the polyunsaturated fatty acids are omega-3 fatty acids.
  - 24. The composition according to claim 1, wherein DHA and EPA comprise at least about 32% w/w of the total lipids in the composition.
  - 25. The composition according to claim 24, wherein DHA and EPA comprise at least about 35% w/w of the total lipids in the composition.
  - 26. The composition according to claim 1, further comprising an antioxidant.
  - 27. The composition according to claim 26, wherein the at least one antioxidant comprises 20 mg/100 ml of the composition.
  - 28. The composition according to claim 26, wherein the antioxidant is selected from the group consisting of vitamin A, vitamin E, beta-carotene, astaxanthin, canthaxanthin, flavonoid and mixture thereof.
  - 29. The composition according to claim 28, wherein the vitamin A is all-trans retinol, the vitamin E is alpha-tocopherol, and the astaxanthin is mainly esterified.
  - 30. The composition according to claim 1, further comprising a metal.
  - 31. The composition according to claim 30, wherein the metal is zinc, selenium or a mixture thereof.
  - 32. The composition according to claim 31, wherein the zinc comprises at least 0.05 mg/100 g of the composition and the selenium comprises less than 3 mg/100 g of the composition.
  - 33. The composition according to any claim 1, wherein the fatty acid composition of the lipids in the composition is about:
  - 34. The composition according to claim 33, wherein the total fatty acid composition of all the lipids in the composition is about:
  - 35. The composition according to claim 34, wherein the total fatty acid composition of all the lipids further is about:
  - 36. The composition according to claim 1, comprising about:
  - 115. A commercial package comprising the composition according to claim 1 together with instructions for its use in treating cancer.
  - 116. A commercial package comprising the composition according to claim 1 together with instructions for its use in treating skin cancer.
  - 117. A commercial package comprising the composition according to claim 1 together with instructions for its use in treating learning disorders.
  - 118. A commercial package comprising the composition according to claim 1 together with instructions for its use in treating dyslexia.
  - 119. A commercial package comprising the composition according to claim 1 together with instructions for its use in treating abnormal motor function.
  - 121. A method of preventing or treating a disease in a subject, said method comprising administering the composition of to claim 1 to said subject, wherein the disease is selected from the group consisting of liver disease, chronic hepatitis, steatosis, liver fibrosis, alcoholism, malnutrition, chronic parenteral nutrition, phospholipid deficiency, lipid peroxidation, disarrythmia of cell regeneration, destabilization of cell membranes, coronary artery disease caused by hypercholesterolemia, high blood pressure, menopausal or post-menopausal conditions, cancer, hypertension, ageing, benign prostatic hyperplasia, kidney disease, edema, skin diseases, gastrointestinal diseases, peripheral vascular system diseases, pregnancy toxemia, neurodegenerative or psychiatric diseases.
  - 122. The method according to claim 121, wherein the peripheral vascular system disease is ulcers, and the neurodegenerative or psychiatric disease is Parkinson'"'"'s, Alzheimer'"'"'s, autism, attention deficit disorder, learning disorders, mood disorders, behavioural disorders, multiple sclerosis or muscular dystrophy.
  - 123. The method according to claim 121, wherein the disease is cancer.
  - 124. The method according to claim 123, wherein the cancer is skin cancer
  - 125. The method according to claim 124, wherein the composition is administered orally or topically.
  - 126. The method according to claim 121, wherein the disease is a learning disorder.
  - 127. The method according to claim 126, wherein the learning disorder is dyslexia.
  - 128. The method according to claim 121, wherein the disease is abnormal motor function.

37. to 114(Canceled).

120. The flavonoid of formula (II):

Specification

Resources

Litigation Campaign Assessment

Current Assignee
Aker BioMarine Antarctic AS (Aker BioMarine ASA)
Original Assignee
Neptune Technologies & Bioressources Incorporated (Quebec)
Inventors
Sampalis, Fotini

Granted Patent

US 8,030,348 B2
Time in Patent Office

Days
Field of Search
US Class Current

424/450
CPC Class Codes

A23J 7/00   Phosphatide compositions fo...

A23K 20/158   Fatty acids; Fats; Products...

A23L 33/115   Fatty acids or derivatives ...

A23L 33/30   Dietetic or nutritional met...

A23V 2002/00   Food compositions, function...

A23V 2250/1846   Phosphatidyl Choline

A23V 2250/1848   Phosphatidyl Ethanolamine

A23V 2250/185   Phosphatidyl Inositol

A23V 2250/1852   Phosphatidyl Serine

A23V 2250/1868   Docosahexaenoic acid

A23V 2250/187   Eicosapentaenoic acid

A23V 2250/70   Vitamins

A61K 2800/522   Antioxidants; Radical scave...

A61K 31/122   having the oxygen directly ...

A61K 31/353   3,4-Dihydrobenzopyrans, e.g...

A61K 31/661   Phosphorus acids or esters ...

A61K 31/6615   Compounds having two or mor...

A61K 31/683   Diesters of a phosphorus ac...

A61K 31/685   one of the hydroxy compound...

A61K 35/612   Crustaceans, e.g. crabs, lo...

A61K 8/553 : Phospholipids, e.g. lecithin

A61K 9/0053 : Mouth and digestive tract, ...

A61K 9/48 : Preparations in capsules, e...

A61P 1/00 : Drugs for disorders of the ...

A61P 1/04 : for ulcers, gastritis or re...

A61P 1/16 : for liver or gallbladder di...

A61P 13/12 : of the kidneys

A61P 17/00 : Drugs for dermatological di...

A61P 25/00 : Drugs for disorders of the ...

A61P 25/16 : Anti-Parkinson drugs

A61P 25/28 : for treating neurodegenerat...

A61P 25/32 : Alcohol-abuse

A61P 3/00 : Drugs for disorders of the ...

A61P 3/06 : Antihyperlipidemics

A61P 35/00 : Antineoplastic agents

A61P 9/00 : Drugs for disorders of the ...

A61P 9/12 : Antihypertensives

A61Q 19/00 : Preparations for care of th...

C07D 407/14 : containing three or more he...

C07F 9/10 : Phosphatides, e.g. lecithin

C07F 9/117 : with cycloaliphatic alcohols

C11B 1/10 : by extracting

View All

Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications

First Claim

4 Assignments

0 Petitions

Accused Products

Abstract

79 Citations

128 Claims

Specification

Solutions

Use Cases

Quick Links

Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications

First Claim

4 Assignments

Subscription Required

Subscription Required

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

79 Citations

128 Claims

Specification

Subscription Required

Solutions

Use Cases

Quick Links